The last few weeks (or is it months?) there's been lots of references to 'the base business.' For some years in the early part of this decade, everyone - generics companies and their followers in the form of analysts and the media - was riveted by the western generics markets -the billions of dollars worth of … Continue reading The return of ‘base business’
Apothecurry 